Business Description
Klaria Pharma Holding AB
SIC : 2834
ISIN : SE0007280326
Total Employee Number:
4Compare
Compare
Traded in other countries / regions
KLAR.Sweden6FN.Germany IPO Date
2020-11-02Description
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting drug products using its proprietary oral film technology. Its drug delivery platform is based on an alginate-based polymer film that adheres to the oral mucosa, allowing active substances to be absorbed directly into the bloodstream rather than through the gastrointestinal tract. This approach is designed to provide faster onset of action and improved bioavailability compared to conventional oral dosage forms. The company applies the platform to develop its own product candidates, including treatments for acute conditions such as migraine and allergic reactions, and also pursues partnership and licensing arrangements with other pharmaceutical companies seeking alternative delivery methods for existing drugs. Klaria is headquartered in Sweden and generates revenue primarily through research and development collaborations, licensing agreements, and milestone payments rather than from marketed products.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.34 | |||||
Equity-to-Asset | -0.9 | |||||
Debt-to-Equity | -0.74 | |||||
Debt-to-EBITDA | -1.12 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -3.88 | |||||
Beneish M-Score | 128.62 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -21.2 | |||||
3-Year EBITDA Growth Rate | 46.1 | |||||
3-Year EPS without NRI Growth Rate | 38.4 | |||||
3-Year FCF Growth Rate | 39.9 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 21.4 | |||||
9-Day RSI | 24.98 | |||||
14-Day RSI | 30.94 | |||||
3-1 Month Momentum % | 25.22 | |||||
6-1 Month Momentum % | 20.55 | |||||
12-1 Month Momentum % | 119.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.2 | |||||
Quick Ratio | 0.2 | |||||
Cash Ratio | 0.14 | |||||
Days Sales Outstanding | 6411.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.2 | |||||
Shareholder Yield % | -1.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -20660.13 | |||||
Net Margin % | -25306.54 | |||||
EBITDA Margin % | -14618.3 | |||||
FCF Margin % | -46338.78 | |||||
OCF Margin % | -46338.77 | |||||
ROA % | -97.91 | |||||
ROIC % | -39.3 | |||||
3-Year ROIIC % | -35.66 | |||||
ROC (Joel Greenblatt) % | -5348.56 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1.41 | |||||
PS Ratio | 12.35 | |||||
EV-to-EBIT | -5.39 | |||||
EV-to-Forward-EBIT | 1 | |||||
EV-to-EBITDA | -7.63 | |||||
EV-to-Forward-EBITDA | 1 | |||||
EV-to-Revenue | 1115.2 | |||||
EV-to-Forward-Revenue | 0.44 | |||||
EV-to-FCF | -3.61 | |||||
Price-to-GF-Value | 2.39 | |||||
Earnings Yield (Greenblatt) % | -18.53 | |||||
FCF Yield % | -33.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Klaria Pharma Holding AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.009 | ||
| EPS (TTM) (€) | -0.018 | ||
| Beta | 2.0813 | ||
| 3-Year Sharpe Ratio | 0.69 | ||
| 3-Year Sortino Ratio | 1.82 | ||
| Volatility % | 101.41 | ||
| 14-Day RSI | 30.94 | ||
| 14-Day ATR (€) | 0.002649 | ||
| 20-Day SMA (€) | 0.062395 | ||
| 12-1 Month Momentum % | 119.63 | ||
| 52-Week Range (€) | 0.0334 - 0.1185 | ||
| Shares Outstanding (Mil) | 245.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Klaria Pharma Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Klaria Pharma Holding AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 150 days | ||
| Third quarter earnings results for 2026 | 2026-11-26 | In 65 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 | 0.09 (+0.00%) | ||
| Annual report for 2025 | 2026-05-29 | 0.07 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-29 | 0.07 (+0.00%) | ||
| General meeting for 2025 | 2026-05-26 10:00 | 0.07 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-20 | 0.07 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-26 | 0.04 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 0.04 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-21 | 0.07 (+0.00%) |
Show
Entries
Klaria Pharma Holding AB Frequently Asked Questions
What is Klaria Pharma Holding AB(FRA:6FN)'s stock price today?
The current price of FRA:6FN is €0.05. The 52 week high of FRA:6FN is €0.12 and 52 week low is €0.03.
When is next earnings date of Klaria Pharma Holding AB(FRA:6FN)?
The next earnings date of Klaria Pharma Holding AB(FRA:6FN) is 2026-11-26.
Does Klaria Pharma Holding AB(FRA:6FN) pay dividends? If so, how much?
Klaria Pharma Holding AB(FRA:6FN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||